Zdrowie i gospodarka · 18/12/2017

FDA Releases Draft Guidance for Developing Targeted Therapies in Rare Disease Molecular Subsets

The US Food and Drug Administration (FDA) has published a draft guidance document outlining its recommendations for grouping patients with different molecular alterations for clinical trial eligibility and evaluating the benefits and risks of targeted therapies in rare diseases with low-frequency molecular subsets.